prioriti review week octob
may miss past week
 realli valu time case miss anyth provid quick summari major event past eek
key event atch upcom eek also link research model applic highlight
frequent inbound question debat topic come investor minut read pleas let us
bristol-my phase sclc miss os phase trial evalu opdivo vs chemotherapi patient ith
sclc fail demonstr statist signific os benefit note data phase evalu opdivo opdivo
yervoy mainten therapi sclc set expect event driven may readout earli
 thought readout
fda lift clinic hold vertex partner crispr tx sickl cell manag reiter plan initi
phase trial scd year-end clinic progress made ou ith recruit transfusion-depend beta-
thalassemia phase underw ay germani uk thought clinic progress
celgen announc posit data phase style studi scalp psoriasi phase trial evalu otezla apremilast
patient ith moder sever scalp psoriasi met primari endpoint scpga scalp physician global assess respons
statist signific also reach secondari endpoint hole bodi itch nr safety/toler profil
consist ith previou seen prior otezla trial
submit mma esketamin nasal spray patient treatment-resist depress nda submiss fda
previous submit esketamin nasal spray trd
sandoz reach settlement humira us late septemb settlement mark anoth ith
humira franchis us competitor biosimilar humira ill like enter market note ever
biosimilar expect enter market eu next eek octob
bioxcel submit ind treatment emerg neuroendocrin prostat cancer bioxel intend studi dipeptidyl
peptidas dpp inhibitor fibroblast activ protein blocker combin ith merck keytruda tnepc
previous show activ melanoma establish safeti profil inc initi overw eight
merck purchas imaginab t-cell imag agent merck intend use agent hich monitor t-cell chang
pet scan i/o clinic studi compani also make equiti invest imaginab
receiv fda approv xarelto reduct cv event cad pad patient line extens make xarelto
first factor xa inhibitor approv patient live ith condit
bristol-my announc collabor compugen advanc solid tumor term agreement
compani ill evalu anti-pvrig antibodi combin ith opdivo patient ith advanc solid tumor includ
nsclc ovarian breast endometri
celgen announc expans on-going collabor evotec expand ipsc collabor ill includ addit cell
line neurogen diseas term celgen ill make up-front payment evotec
report data phase stelara studi uc patient phase singl iv dose trial show ed clinic remiss
greater proport uc patientsw ho previous experienc inadequ respons ere intoler convent biolog
therapiesv placebo demonstr statist signific key secondari endpoint addit dose stelara
show ed stat sig improv ibdq ell key marker inflamm includ crp fecal lactoferrin calprotectin
neurocrin enter clinic collabor disord agreement compani ill
leverag jnana drug discoveri platform multipl target disord ill respons lead optim
novel compound identifi
boehring ingelheim present data empa-reg outcom trial trialevalu jardianc adult
patient ith ed increas estim life expect hen compar patient placebo estim mean
surviv year old year vs year mean surviv differ year peopl age year
old mean surviv differ year year year year respect
celgen present data phase trial oral ozanimod ectrim tw phase trial radianc part
sunbeam demonstr reduct annual relaps rate mri lesion month patient ith earli relaps multipl
sclerosi ms vs patient ith advanc diseas state post hoc analysi pool data trial
receiv orphan drug design treatment multipl myeloma
proprietari research past week
 biopharmaceut takeaw ay generic/biosimilar symposium
client ask
investor ask follow ing topic phone call email in-person market meet
implic clinic hold lift vrtx/crsp scd hile admit focu larg remain
compani cf franchis particular upcom phase tripl combo readout anticip investor interest
seem slow ly shift vrtx early-stag pipelinea trend expect continu ith sever de-risk event anticip
near-term overal encourag vertex earli effort expand product portfolio beyond cf hile recent lift
clinic hold doesnt come surpris given recent convers ith manag major stock-mov event
view posit step compani emerg rare diseas portfolio look addit updat program
near-term ith phase trial expect initi end yearand on-going progress made ph
underw ay germani uk
overal expect earn biopharma hile recent correct biopharma ad
uncertainti head elect cycl earn note momentum sector shift posit direct
throughout year believ sentiment ill trend upw ard remaind year fund flow
healthcar remain posit year thu far hich think like driven continu de-risk novel
platform technolog hile point strength us dollar potenti risk head quarter large-
cap believ overal modest expect drive strength mani compani ithin coverag continu believ
meaning large-scal and/or high-impact clinic readout may necessari increas broader interest space
overal remain posit space head earn biopharmaceut earn preview
takeaway barclay generics/biosimilar symposium though price rhetor rebat reform continu
top mind mani investor remain opinion littl chang ill come effect biosimilar industri
near-term gener remain key valu contributor healthcar ecosystem offer save us ever
challeng persist bring gener market inde rate first-cycl approv anda year agolow
comparison first-cycl approv rate brand drug remain low ith speaker estim rate
today dynam profound biosimilar uptak fallen short expectationsleav key
compon administr initi blueprint releas earlier year view ont like see rapid price declin like
usual observ follow ing launch tradit gener least biosimilar market brand
productw ith implic brand manufactur quick take event takeaw ay
generic/biosimilar symposium
watch week ahead
clinic trial read-out regulatori event expect near-term
dupix sbla asthma pdufa date
subgroup analysi phase trial confer call follow
glpg falcon cystic fibrosi phase dose studi corrector corrector potenti expect
phase data expect
phase data opdivo opdivo yervoy mainten sclc expect
european societi medic oncolog esmo munich germani octob
american colleg rheumatolog acr/arhp chicago il octob
societi immunotherapi cancer ashington dc novemb
american societi hematolog san diego ca decemb
let us know question comment geoff jason olivia
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog price target base npv analysi forecast risk-adjust sale
agit begin assum pivot data earli fda approv ith year
exclus also forecast risk-adjust sale prostat neuroendocrin pancreat cancer assum
potenti launch forecast sale conserv assum termin valu use discount rate
given earli stage program given assumpt deriv valuat
net cash npv support price target
risk may imped achiev barclay research valuat price clinic risk bioxcel
limit clinic data demonstr util main asset patient failur suffici demonstr
clinic efficaci patient appropri commensur safeti level could significantli affect near-term valu
share note even late-stag asset fail clinic studi approv medic ithdraw market
varieti reason
competit risk bioxcel develop asset highli competit oncolog neurosci space ith compani much
along develop mani hich establish sale forc space ith long-stand relationship ith
prescrib care-giv mani also strong commerci footprint ith establish manufactur distribut netw ork
financ risk bioxcel commerci revenu expect unprofit time remain risk
insolv dilut sharehold futur capit rais via debt equiti note compani limit
mean sustain unforeseen delay clinic develop regulatori process manufactur
distribut potenti asset potenti necessit addit capit infus
regulatori risk none bioxcel therapi approv commerci use even therapi success complet
develop regulatori pathw ay long uncertain ith regul potenti call addit data full studi
delay potenti launch develop asset
commerci risk even bioxcel therapi receiv regulatori approv commerci therapi ill like
expens could face reimburs headw ind meet consensu sale expect note compani
current establish sale forc necessit invest relationship ith neurologist hich may
serv slow dampen uptak
rate price target histori
histor stock price price target may adjust stock split dividend
price sourc thomson reuter last avail close price relev trade market unless anoth time
sourc indic
